-
Je něco špatně v tomto záznamu ?
The effect of combined diet containing n-3 polyunsaturated fatty acids and silymarin on metabolic syndrome in rats
M. Poruba, P. Anzenbacher, Z. Racova, O. Oliyarnyk, M. Hüttl, H. Malinska, I. Markova, S. Gurska, L. Kazdova, R. Vecera
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- antioxidancia metabolismus MeSH
- dieta * MeSH
- dyslipidemie terapie MeSH
- exprese genu účinky léků MeSH
- hypertriglyceridemie komplikace farmakoterapie genetika MeSH
- krysa rodu rattus MeSH
- lipidy krev MeSH
- metabolický syndrom etiologie prevence a kontrola MeSH
- metabolismus lipidů účinky léků genetika MeSH
- modely nemocí na zvířatech MeSH
- omega-3 mastné kyseliny aplikace a dávkování MeSH
- oxidační stres účinky léků MeSH
- peroxidace lipidů účinky léků MeSH
- potkani Wistar MeSH
- rybí oleje MeSH
- silymarin aplikace a dávkování MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
The risk of development of metabolic syndrome can be increased by hypertriglyceridemia. A search for effective therapy is a subject of considerable attention. Therefore, our hypothesis is that the fish oil (containing polyunsaturated fatty acids; n-3 PUFA) in a combination with silymarin can more effectively protect against hypertriglyceridemia-induced metabolic disturbances. The study was conducted using a unique non-obese strain of rats with hereditary hypertriglyceridemia an accepted model of metabolic syndrome. Adult male rats were treated with n-3 PUFA (300 mg/kg/day) without or with 1 % micronized silymarin in a diet for 4 weeks. The treatment with the diet containing n-3 PUFA and silymarin significantly reduced concentrations of serum triglycerides (-45 %), total cholesterol (-18 %), non-esterified fatty acids (-33 %), and ectopic lipid accumulation in skeletal muscle (-35 %) compared to controls. In addition, an increase in Abcg5 and Abcg8 mRNA expression (as genes affecting lipid homeostasis) as well as in protein content of ABCG5 (+78 %) and ABCG8 (+232 %) transporters have been determined in the liver of treated rats. Our findings suggest that this combined diet could be used in the prevention of hypertriglyceridemia-induced metabolic disorders.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21028164
- 003
- CZ-PrNML
- 005
- 20220328134205.0
- 007
- ta
- 008
- 211105s2019 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934322 $2 doi
- 035 __
- $a (PubMed)31755289
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Poruba, Martin $7 xx0230224 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 245 14
- $a The effect of combined diet containing n-3 polyunsaturated fatty acids and silymarin on metabolic syndrome in rats / $c M. Poruba, P. Anzenbacher, Z. Racova, O. Oliyarnyk, M. Hüttl, H. Malinska, I. Markova, S. Gurska, L. Kazdova, R. Vecera
- 504 __
- $a Literatura
- 520 9_
- $a The risk of development of metabolic syndrome can be increased by hypertriglyceridemia. A search for effective therapy is a subject of considerable attention. Therefore, our hypothesis is that the fish oil (containing polyunsaturated fatty acids; n-3 PUFA) in a combination with silymarin can more effectively protect against hypertriglyceridemia-induced metabolic disturbances. The study was conducted using a unique non-obese strain of rats with hereditary hypertriglyceridemia an accepted model of metabolic syndrome. Adult male rats were treated with n-3 PUFA (300 mg/kg/day) without or with 1 % micronized silymarin in a diet for 4 weeks. The treatment with the diet containing n-3 PUFA and silymarin significantly reduced concentrations of serum triglycerides (-45 %), total cholesterol (-18 %), non-esterified fatty acids (-33 %), and ectopic lipid accumulation in skeletal muscle (-35 %) compared to controls. In addition, an increase in Abcg5 and Abcg8 mRNA expression (as genes affecting lipid homeostasis) as well as in protein content of ABCG5 (+78 %) and ABCG8 (+232 %) transporters have been determined in the liver of treated rats. Our findings suggest that this combined diet could be used in the prevention of hypertriglyceridemia-induced metabolic disorders.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antioxidancia $x metabolismus $7 D000975
- 650 12
- $a dieta $7 D004032
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a dyslipidemie $x terapie $7 D050171
- 650 _2
- $a omega-3 mastné kyseliny $x aplikace a dávkování $7 D015525
- 650 _2
- $a rybí oleje $7 D005395
- 650 _2
- $a exprese genu $x účinky léků $7 D015870
- 650 _2
- $a hypertriglyceridemie $x komplikace $x farmakoterapie $x genetika $7 D015228
- 650 _2
- $a metabolismus lipidů $x účinky léků $x genetika $7 D050356
- 650 _2
- $a peroxidace lipidů $x účinky léků $7 D015227
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolický syndrom $x etiologie $x prevence a kontrola $7 D024821
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a silymarin $x aplikace a dávkování $7 D012838
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Anzenbacher, Pavel, $d 1947- $7 xx0034447 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Rácová, Zuzana $7 xx0109661 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Oliyarnyk, Olena $7 xx0095365 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Hüttl, Martina $7 xx0230591 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Malínská, Hana $7 xx0158953 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Marková, Irena $7 xx0161888 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Gurská, Soňa $7 xx0267298 $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Kazdová, Ludmila, $d 1938- $7 xx0053119 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Večeřa, Rostislav, $d 1965- $7 mzk2004236742 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 68, Suppl 1 (2019), s. S39-S50
- 773 0_
- $t 69th Czech-Slovak pharmacological days $g (2019), s. S39-S50 $w MED00208902
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31755289 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20211105 $b ABA008
- 991 __
- $a 20220328134203 $b ABA008
- 999 __
- $a ok $b bmc $g 1728767 $s 1148709
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 68 $c Suppl 1 $d S39-S50 $e 20191122 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- BMC __
- $a 2019 $d S39-S50 $m 69th Czech-Slovak pharmacological days $x MED00208902
- LZP __
- $b NLK118 $a Pubmed-20211105